In multiple clinical pharmacology studies in patients with T2DM, exenatide was shown to modulate fasting serum insulin and glucagon in a manner dependent upon exenatide dose and ambient glucose concentrations [60-62,64,69,77-80]. This evidence concerns the gene INS and type 2 diabetes mellitus.